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Abstract
The cyclooxygenase (COX) exists in two main isoforms, COX-1 and COX-2, which are present in the renal system to ensure its homeosta-
sis. However, in different clinical situations, these enzymes can play a physiologic role in maintaining the integrity of this organ, and also 
be associated with the worsening of tissue injuries/damage. In this sense, an explanation of the true biological function of the isoforms of 
COX enables a better understanding of the physiology and pathology of the kidney, as well as a better understanding of the consequences 
of its inhibition by the use of drugs. This review aimed to study the biological role of the COX enzyme in the renal system in different 
clinical situations.
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Resumen
La ciclooxigenasa existe en dos isoformas principales: COX-1 y COX-2, estas se encuentran presentes en el sistema renal como parte de su 
homeostasis. Sin embargo, en algunas situaciones clínicas, las dos enzimas pueden desempeñar un papel en el mantenimiento de la integri-
dad de este órgano, y en otras pueden estar asociadas a la evolución de daños y lesiones en los tejidos. En este sentido, el conocimiento de 
la verdadera función biológica de las isoformas de la COX permite una mejor comprensión de la fisiología y patología del riñón, así como 
una mejor comprensión de las consecuencias de su inhibición por el uso de medicamentos. El objetivo de esta revisión es estudiar la función 
biológica de la enzima COX en el sistema renal en diferentes situaciones clínicas.
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Introduction
Cyclooxygenase (COX), the main catalyst enzyme in the prostanoid synthesis, has two main known isoforms, COX-
1 and COX-21,2. COX-1, which is responsible for 
physiological functions, is expressed mainly as 
a constitutive isoform3 and, in normal conditions 
and in distinct regions of the kidney, generates 
prostaglandins that are responsible for vasodilation 
and diminished vascular resistance, ensuring 
adequate blood flow4. On the other hand, COX-2, 
initially considered pathological, is highly expressed 
in the presence of damaging stimuli1. However, this 
isoform is now also known to appear constitutively 
in some tissues, like in the kidney, where it is 
responsible for ensuring the tubuloglomerular 
feedback, contributing to the establish homeostasis5.
In this sense, although the COX functions have 
been well-studied in normal situations, studies 
have demonstrated that, facing different clinical 
situations, its isoforms may assume different 
roles. In cases of hypovolemia and hypertension, 
this enzyme can develop the physiological role of 
maintaining the integrity of the kidney, as well as 
becoming associated with the aggravation of tissue 
lesion/damage, as observed in the polycystic kidney 
disease4, 6-10.
Thus, clarifying the true biological functioning 
of the COX isoforms enables a better comprehen-
sion of the kidney physiology and pathology, as 
well as a better understanding of the consequen-
ces of the isoforms’ inhibition by medication. This 
review intended to study the biological role of the 
COX enzyme in the renal system in different clini-
cal situations.
Cyclooxygenase
The cyclooxygenase (COX) is the main enzyme 
that catalyses the prostaglandin synthesis from ara-
chidonic acid. This way, it originates different pros-
tanoids with different functions in the organism1. 
This process is initiated with the archidonic acid, 
present in the lipid bilayer of the cell membrane, 
triggering the prostanoid biosynthesis pathway due 
to the presence of different stimuli11-16. The pathway 
involves a sequence of three main steps. Initially, 
the arachidonic acid is liberated, by hydrolysis, 
through the action of the phospholipase A2 enzyme 
(PLA2). Once liberated, the second step begins, with 
oxygenation by the prostaglandin G/H synthase, 
or cyclooxygenase, resulting in the prostaglandin 
endoperoxide G2 (PGG2). In sequence, the same 
COX enzymes reduce the PGG2 into prostaglandin 
H2 (PGH2)
15-17. The prostaglandin G/H synthase 
has the cyclooxygenase and peroxidase catalytic 
sites. The former converts arachidonic acid into 
PGG2, which is acted upon by the peroxidase 
enzyme and reduced to the unstable intermediate, 
PGH2, responsible for the formation of different 
kinds of prostanoids such as prostacyclin (PGI2), 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), 
prostaglandin F2α (PGF2α) and thromboxane A2 
(TXA2), through its conversion by the tissue-
specific isomerases13,18-20. These prostanoids 
provoke different actions in the organism through 
specific receptors, which depend on the type of cell 
and tissue involved in the process (Figure 1) 20-22.
There are different isoforms of COX, but the 
most studied are COX-1 and COX-21. COX-1 was 
initially named physiological or constitutive for 
being present in the majority of tissues and being 
expressed in an almost steadily fashion13,19, 23. Its 
main role consists of maintaining a basal rate of the 
biosynthesis of prostanoids in the body, in order to 
promote their rapid, short-duration increase. On the 
other hand, COX-2 is hardly found in most tissues, 
but its production increases by approximately 20 ti-
mes in the presence of inflammatory stimuli. For 
this reason, it has been called the pathological or in-
duced enzyme13,19,23,24. However, recent studies have 
demonstrated that it is also found constitutively in 
some tissues, being responsible for the formation of 
prostanoids that maintain homeostasis in different 
organs and systems of the body 1, 24-26. 
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Figure 1. Prostanoid biosynthesis pathway. Source: author
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Cyclooxygenase in renal function
Normal Function
COX-1 is found in the glomeruli, in the medu-
llary and cortical region of the collecting ducts and 
in the afferent and efferent arterioles27, ensuring the 
maintenance of the kidney’s physiological func-
tions, such as hemodynamic regulation and glo-
merular filtration rate (GFR) 13, 28-30. This isoform 
produces PGE2 and PGD2, which antagonize the va-
soconstrictive action of angiotensin II (Ang II), and 
inhibit the release of norepinephrine, respectively31.
In this way, these prostanoids promote 
vasodilation, increasing the perfusion of the organ 
and causing redistribution in the blood flow from the 
renal cortex to the nephrons in the intramedullary 
region31. Additionally, the PGE2, alongside the 
PGF2α, possess the diuretic and natriuretic effects 
and the PGE2, like the PGI2, antagonize the action 
of vasopressin31.
Although COX-2 has been initially considered 
pathological, is also found constitutively in the 
kidneys29,32. Studies in COX-2 knockout rats 
demonstrate a grave defect in the renal formation, 
suggesting this isoform performs an important task 
in the development of the kidneys33.
COX-2 is situated in particularly important re-
gions for the renal function, concentrating mainly 
in the medullary region, and in the cortical region 
to a lesser extent32. Specifically, it can be found in 
smooth muscle cells of the afferent and efferent ar-
terioles, in the endothelium (straight venules and 
vasa recta), renal artery, interstitial fibroblasts, and 
in podocytes in healthy kidneys34. It is also expres-
sed in the thick ascending limb of the Henle loop, in 
addition to being found in the macula densa, which 
is responsible for mediating the interaction between 
glomerular filtration and proximal reabsorption, 
and for controlling the levels of sodium and potas-
sium ions in the lumen of the distal tubule through 
the renin–angiotensin–aldosterone system7, 8, 27, 28, 35.
 Like in COX-1, prostaglandins (PGs) also de-
rive from COX-2, being important physiological 
modulators of vascular tone and hydric balance in 
the kidneys13, 35. The prominent PGs in renal tissue 
are PGE2 and PGI2, where PGE2 is synthesized by 
the tubular epithelium and interstitial cells, expres-
sed in the renal tubules regulating the transport of 
chloride and sodium in the Henle loop, besides au-
xiliating water transport and blood flow. PGI2 is lo-
cated in the renal cortex, controlling the glomerular 
filtration rate and renin secretion7, 29. 
Hypovolemia
Hypovolemia is characterized by a decrease in 
blood volume, being mainly the result of excessive 
loss of water in the kidney or hemorrhage. As a con-
sequence, arterial pressure drops, with the possibili-
ty of hypovolemic shock and death13, 31.
In a state of hypovolemia with consequent 
depletion of sodium levels, there is an increase 
of COX-2 in the cortical region, and a decrease 
of its expression in the medullary region, causing 
the renin–angiotensin–aldosterone system to be 
activated. The juxtaglomerular cells secrete the 
hormone renin, which contributes to the formation 
of Ang II, responsible for the vasoconstriction of 
the efferent arteriole together with norepinephrine, 
guaranteeing the increase of the intraglomerular 
hydrostatic pressure. The hormone also stimulates the 
secretion of aldosterone, responsible for promoting 
the reabsorption of sodium and, ultimately, inducing 
the liberation of antidiuretic hormone (ADH), 
which increases water and urea reabsorption. At the 
same time, angiotensin stimulates the synthesis of 
renal vasodilator prostaglandins (afferent arteriole), 
which guarantees the tubuloglomerular feedback, 
reestablishing the glomerular filtration rate, and 
ensuring normal blood flow to protect the kidney 
from acute functional deterioration5, 13, 31, 35-37.
The administration of selective or non-selecti-
ve COX-2 non-steroidal anti-inflammatory drugs 
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(NSAIDs) prevents the release of renin and, conse-
quently, the restoration of renal function38. 
Hypotension
Hypotension leads to low effective filtration 
pressure in the glomeruli, which can become a state 
of chronic kidney disease. In these situations, the 
function of compensatory vasoconstrictor and va-
sodilator prostaglandins (PGE2 e PGI2), provenient 
from COX-2, is amplified in an attempt to maintain 
adequate organ perfusion39, 40.
This action favors the resorption of sodium/
water, which maintains a renal homeostasis by the 
GFR. In agreement, the thromboxane (TX), produ-
ced by COX-1, provokes vasoconstriction. Thus, 
NSAIDs may be use carefully because they can act 
blocking the COX-1 and COX-2 enzymes and, con-
sequently this mechanism41. In the study of Calistro 
Neto and group (2015), animals that use Parecoxib, 
a selective inhibitor of COX-2, had renal detrimen-
tal effect by the non-activation of renin–angioten-
sin–aldosterone system41. 
In disagreement with the results, Tunctan and 
group (2013) declare that COX-2 induces hypoten-
sion, because their vasodilatory capacity. This study 
concludes that the use of a COX-2 inhibitor is able 
to restore blood pressure42. 
Renal ischemia/reperfusion injury
The pathology of this injury is marked by the pre-
sence of an inflammatory response and oxidati-
ve stress43. The COX-2 is highly expressed and is 
able to aggravate the inflammation. So, the use of a 
NSAID that selectively inhibits COX-2, also called 
coxib, can be benefic to the renal function by pre-
vention of oxidative injury 27, 43, 44.
More specifically, the use of parecoxib, a coxib, 
resulted in renal protection41. A similar study that 
uses indomethacin, a non-selective NSAID, and ro-
fecoxib, a coxib, showed that both drugs were asso-
ciated with improved renal function and a reduction 
of proinflammatory cytokine levels45. 
To finish, the use of nimesulida, a COX-2 
selective inhibitor drug, also prevented the renal 
damage46. 
Hypertension
In contrast, in a state of hypertension, COX-2 
expression will also be increased. However, unlike 
in hypotension, this increase will occur in the me-
dullary tissues in an attempt to ensure that the va-
soconstrictive and hypertensinogenic effects of Ang 
II be softened, aiming then to reestablish sodium 
and water regulation, as well as the maintenance of 
medullary blood flow47. In this sense, the use of any 
NSAIDs aggravates the hypertension and it must 
be avoided. The block of PGE2 by drugs lead to 
sodium retention which exacerbate the deleterious 
process38. 
Fibrosis
Another alteration of the renal system is fibrosis. 
It is characterized by the development of glomeru-
lar sclerosis and interstitial fibrosis, being one of the 
consequences of the final stages of several chronic 
kidney diseases48. The COX-2 isoform guarantees 
protection against fibroses and, by virtue of that, the 
high quantity of PGE2 generated can hinder the de-
velopment of the condition48. 
Polycystic kidney disease
As well as renal ischemia/reperfusion injury, the 
COX enzyme can also present deleterious effects in 
other situations in the renal system. In the presence 
of polycystic kidney disease, a autosomal dominant 
renal disorder frequently hereditary in nature cha-
racterized by the continuous growth of cysts, there 
is an increase in activity of PGE2 and PGI2 (derived 
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from both isoforms of COX), responsible for stimu-
lating cellular proliferation, secretion of fluid and 
cyst formation49.
In a humam study, by the blood collection, it 
was found that patients with autosomal polycystic 
kidney disease (APKD) have high levels of COX 
compared to the health group9. Agreeing with these 
authors, by culture of epithelial cells from cysts of 
patients with APKD, Xu et al. (2012)50 concluded 
that the use of a COX-2 inhibitor is capable to redu-
cing the epithelial proliferation, promoting apopto-
sis of these, and decrease the PGE2 synthesis
50.
Thus, the inhibition of COX-1 or COX-2 by 
NSAIDs may reduce the progression of the disea-
se10. 
Diabetes mellitus
Diabetes mellitus is a chronic disease that leads 
to kidney damage. In this context, it has been found 
that inducing COX-2 in the proximal tubules may 
lead to an increase in PGE2 production and in pro-
tein excretion in diabetic mice51. Even so, studies 
are showing that COX-2 and PGE2 production were 
increased in patients with diabetes mellitus, leading 
to the use of a COX-2 inhibition which can attenua-
te different renal diseases52.
In agreement with these findings, a study 
conducted in animal models has determined 
that, when administering rofecoxib, a selective 
COX-2 inhibitor, protenuria levels in Zucker rats 
normalized53. In contrast, there are reports in the 
literature that in Zucker rats (obese) and db/db mice 
(insulin resistant), renal COX-2 has been positively 
regulated54, 55. 
Diabetic patients have an excessive polyuria 
and urinary concentration of PGE2. So, the use of a 
NSAID must be used to control the levels of PGE2 
and adequate the urine concentration27.
In the study of Liu and group (2016), Ibuprofen 
was administered in rats with renal impairment and 
type 1 diabetes. The use of ibuprofen was able to 
decrease urinary protein excretion, blood urea ni-
trogen, glomerular basement membrane thickening, 
renal fibrosis, COX-2, and interleukin 1β (IL-1β) 
level, suggesting that this drug can prevent the de-
velopment of renal damage in the diabetic group56. 
Kidney inflammation
The expression of COX-2 enzyme is conside-
rably increased in response to renal tissue inflam-
mation57. When activated in pathological processes, 
there is the formation of proinflammatory cytokines 
(interleukin-1 and TNF-α) and reactive oxygen spe-
cies (ROS), which play a critical role in the renal 
physiopathology40, 58. There is also a positive feed-
back through the signaling pathways that promote 
the development and progression of the disease40, 
58, 59.
Authors state that inflammation is the causal 
factor that collaborates with renal lesion, especially 
with PGE2 which, although in physiological con-
ditions contributes to the maintenance of renal ho-
meostasis40, 60, 61, in pathological situations might be 
responsible for unleashing a deleterious process40.
This difference in the PGE2 action in various 
clinical situations is due to its attachment to 
four receptors, EP1, EP2, EP3 and EP440,62. EP1 
is responsible for natriuresis and diuresis and 
regulation of blood pressure. Receptors EP2 and 
EP4 have been reported to activate production 
of adenylate cyclase and increase (cAMP) and to 
increase water reabsorption, on the other hand, EP3 
have the opposite effects27, 61, 63, 64.
A study conducted in rats subjected to 
nephrectomy has found that, after 4 weeks, the 
animals presented increased levels of urea and 
creatinine, reduction of creatinine clearance, 
and disorders in the metabolism of calcium and 
phosphorus, highlighting significant kidney 
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failure40. However, in rats where PGE2 production 
was suppressed, there was a notable and stable 
improvement in all those alterations, suggesting that 
the PGE2-induced inflammation may be involved in 
the progression of renal lesion40.
The table 1 presents a summary of the COX 
(COX-1 and COX-2) system roles in the different 
clinical situations mentioned.
Conclusion
Both COX isoforms play important roles in 
the regulation of renal homeostasis. However, in 
different clinical situations, their functions might be 
altered. Thus, the exactly role of COX-1 and COX-
2 and their inhibition by the use of NSAIDs still 
remains controversial. So, it is important that the 
health care professional be aware of these possible 
alterations in order to provide the best clinical 
course of action.
Table 1. 
Biological functions of the COX enzyme in different clinical situations.
Clinical situation Biological COX functions
COX-1 COX-2
Normal function GFR and hemodynamic regulation; blood flow redistribution; diuretic and natriuretic effect.
Hydric balance and vascular tone modulation; 
renin secretion and GFR control.
Hypovolemia -
Activation of the renin–angiotensin–aldosterone 
system – tubuloglomerular feedback – GFR 
reestablishment
Hypotension TX - vasoconstrictor
↑ Function of compensatory vasoconstrictor 
and vasodilator PGs – maintain adequate organ 
perfusion
Renal ischemia/ reperfusion injury - ↑ Inflammatory response and oxidative stress
Hypertension -
Lessens vasoconstrictive and hypertensinogenic 
effects and reestablish sodium and water 
regulation.
Fibrosis - Protection – stop condition development
Polycystic Kidney Disease Stimulate cellular proliferation, fluid secretion and cyst formation.
Diabetes mellitus - ↑ Protein excretion.
Kidney inflammation - Formation of proinflammatory cytokines and ROS – development and progression of disease.
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